IL6 and neoplasm: Importantly, Sulciner and colleagues previously reported that using proresolving lipids such as RvE1 in preclinical models of tumor growth, that relied on chemotherapy-induced cell debris, counteracted tumor progression through stimulation of macrophage phagocytic activity and decrease of their proinflammatory cytokine (TNFα, IL-6) release that occurred in a ChemR23-dependent process (4).